IFRD1 and dry eye syndrome: In uninfected KCs, treatment with cetuximab decreased the already low levels of IFRD1 protein, and although this led to increased cytokine gene expression after IFN-γ and TNF-α-stimulation, no additional increase in the already high levels of secreted cytokines was observed (Fig. 3g,h).